ACCESS Newswire·May 20, 2026, 8:00 AM ET

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the journal Advances in Redox Research on May 20, 2026.
The study demonstrated dose-dependent survival improvements in a Wilson's disease zebrafish model characterized by ATP7B deficiency.
Key findings included reduced hepatic copper burden, decreased copper-associated oxidative stress, & improved liver injury biomarkers such as ALT, AST, & bilirubin.
Telomir-Zn treatment attenuated intracellular calcium dysregulation, preserved metabolic viability, & reduced tissue degeneration in the model.
The drug disrupted ROS-Ca²⁺ feedback amplification cascades associated with copper toxicity & mitochondrial injury.
This publication marks the first peer-reviewed data for Telomir-Zn in Wilson's disease & supports the company's broader mechanistic approach targeting oxidative stress & metal homeostasis.
The findings are consistent with the profile of Telomir-Zn's lead program for Triple-Negative Breast Cancer, which received FDA IND clearance in April 2026.
Telomir Pharmaceuticals plans to evaluate the Wilson's disease program while advancing its TNBC program toward Phase 1/2 clinical initiation.